Inflammatory Disease Candidate Reaches End of the Line

Company halts clinical studies and any further molecule development.

 

RG6174 (GDC-0334) is a drug that as being developed by Genentech for the treatment of inflammatory diseases. The candidate had reached the phase 1 clinical study stage late in 2017, but the company was unable to enroll a sufficient number of patients and after extending the targeted closing date, the trial was canceled. Roche has since terminated molecule development.

 

The company never disclosed much information about the program and has not discussed its mechanism of action nor any specific targeted indications. The termination was disclosed as part of a quarterly update.

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.